LNWWM
DNA icon

Laird Norton Wetherby Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-369
Closed -$17.1K – 938
2024
Q1 		$17.1K Buy
369
+88
+31% +$4.55K ﹤0.01% 960
2023
Q4 		$19K Sell
281
-92
-25% -$5.63K ﹤0.01% 920
2023
Q3 		$27K Buy
373
+20
+6% +$1.6K ﹤0.01% 902
2023
Q2 		$26.3K Sell
353
-187
-35% -$11.1K ﹤0.01% 948
2023
Q1 		$28.7K Sell
540
-227
-30% -$14.4K ﹤0.01% 921
2022
Q4 		$51.8K Buy
+767
New +$70.5K ﹤0.01% 891

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's DNA Position: Q2 2024 in Review

Laird Norton Wetherby Wealth Management sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 369 shares — an estimated $17.1K sold.

Laird Norton Wetherby Wealth Management first reported a position in DNA in Q4 2022 and held it in 6 quarters. The position peaked at $51.8K in Q4 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Laird Norton Wetherby Wealth Management reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Laird Norton Wetherby Wealth Management sold 369 Ginkgo Bioworks shares in Q2 2024, an estimated $17.1K.
  • Laird Norton Wetherby Wealth Management first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 6 quarters.
  • Laird Norton Wetherby Wealth Management's Ginkgo Bioworks position peaked at $51.8K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.